Related Experiment Videos
[Preventive treatment of diabetic microangiopathy: blocking the pathogenic mechanisms]
1Service de Médecine B, Hôpital Lariboisière, Paris, France.
Abstract:
The development of drugs in order to block metabolic pathway of glucose responsible for diabetic vascular dysfunction is in progress. Aldose reductase inhibitors prevent or reduce the different components of vascular dysfunction, cataract, neuropathy and nephropathy in animal models of diabetes. Promising results have been observed in diabetic patients concerning the prevention of neuropathy and of retinopathy. Larger scale studies with the second generation compounds are in progress. Glycation inhibitors, mainly aminoguanidine, have been shown to prevent or reduce vascular dysfunction and microvascular complications in animal models. Trials in diabetic patients with aminoguanidine are just beginning. Anti-oxidant therapy is also at its early stage of development (vitamin E, vitamin C, alpha lipoic acid). Antiplatelet agents (aspirin, ticlopidine) have been demonstrated to reduce the progression of non proliferative diabetic retinopathy. Angiotensin converting enzyme inhibitors are of particular interest in preventing diabetic glomerulopathy.
Insights
New drugs targeting glucose metabolism are being developed to combat diabetic vascular dysfunction. Promising results show potential in preventing diabetic complications like neuropathy and retinopathy.
Area of Science:
- Biochemistry
- Pharmacology
- Diabetology
Context:
- Diabetic vascular dysfunction arises from glucose metabolic pathways.
- Current research focuses on therapeutic interventions to mitigate these complications.
Purpose:
- To review emerging drug classes for treating diabetic vascular complications.
- To highlight the therapeutic potential of aldose reductase inhibitors, glycation inhibitors, antioxidants, antiplatelet agents, and ACE inhibitors.
Summary:
- Aldose reductase inhibitors show promise in preventing neuropathy and retinopathy in diabetic patients.
- Glycation inhibitors like aminoguanidine are in early clinical trials for vascular dysfunction.
- Antioxidant therapies and antiplatelet agents are under investigation for managing diabetic microvascular complications.
Impact:
- These drug development efforts aim to improve outcomes for diabetic patients by preventing or reducing vascular damage.
- Successful interventions could significantly reduce the burden of diabetic complications such as retinopathy, neuropathy, and nephropathy.